Imbria Pharmaceuticals has secured $57.5m in a Series B funding round to support the progression of ninerafaxstat through a double-blind Phase IIb FORTITUDE-HCM trial in non-obstructive hypertrophic cardiomyopathy (nHCM).
BridgeBio Pharma has received the Japanese Ministry of Health, Labour and Welfare approval for Beyonttra, a brand name for acoramidis, for treating adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).
The US Food and Drug Administration (FDA) has accepted a supplemental new drug application (sNDA) of Alnylam Pharmaceuticals’ vutrisiran for review.
AstraZeneca has signed an exclusive agreement to license CSPC Pharmaceutical’s new lipid-lowering therapy, YS2302018, for treating patients with dyslipidaemia.
The US Food and Drug Administration (FDA) has granted approval for Novo Nordisk's Wegovy (semaglutide 2.4 mg) for lowering cardiovascular risks in adults with established cardiovascular disease (CVD) who are overweight or obese.
UK-based biotechnology company IsomAb has secured £7.5m (approximately $9.4m) in a seed funding round to expedite the development of its lead candidate targeting peripheral arterial disease.
Innovent Biologics has signed a partnership agreement with Sanegene Bio to jointly develop an angiotensinogen (AGT) directed siRNA drug candidate, SGB-3908, to treat hypertension.
Amarin has entered into an exclusive marketing and commercialisation agreement with Neopharm for VAZKEPA in the State of Israel, Gaza, West Bank and the territories of the Palestinian Authority.
Eleven Therapeutics has entered into a research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics.
Clinical-stage biotechnology company Tenaya Therapeutics has received fast track designation from the US Food and Drug Administration (FDA) for its gene therapy product candidate, TN-201.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.